for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BioNTech SE - ADR

BNTX.O

Latest Trade

77.00USD

Change

-0.08(-0.10%)

Volume

3,038,220

Today's Range

74.03

 - 

78.54

52 Week Range

12.53

 - 

105.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
77.08
Open
77.09
Volume
3,038,220
3M AVG Volume
63.54
Today's High
78.54
Today's Low
74.03
52 Week High
105.00
52 Week Low
12.53
Shares Out (MIL)
226.26
Market Cap (MIL)
18,202.10
Forward P/E
-112.24
Dividend (Yield %)
--

Next Event

Q2 2020 BioNTech SE Earnings Call

Latest Developments

More

Biontech And Fosun Pharma Announce Start Of Clinical Trial Of Mrna-Based Covid-19 Vaccine Candidate In China

Biontech Announces Strategic Collaboration With Regeneron

Biontech SE Files For Offering 5 Million ADSS

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About BioNTech SE - ADR

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Industry

Biotechnology & Drugs

Contact Info

An der Goldgrube 12

55131

Germany

+49.6131.90840

https://biontech.de/

Key Stats

2.50 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2019

0.1K

2020(E)

0.3K
EPS (EUR)

2019

-0.850

2020(E)

-0.192
Price To Earnings (TTM)
--
Price To Sales (TTM)
113.46
Price To Book (MRQ)
38.16
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
21.25
LT Debt To Equity (MRQ)
15.95
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Pfizer to make Gilead's COVID-19 treatment remdesivir

Pfizer Inc <PFE.N> said on Friday it signed a multiyear agreement to make COVID-19 treatment remdesivir for developer Gilead Sciences Inc <GILD.O>, which is under pressure to increase tight supplies of the antiviral drug.

U.S. to pay $1 billion for 100 million doses of Johnson & Johnson's COVID-19 vaccine candidate

The United States government will pay Johnson & Johnson <JNJ.N> over $1 billion for 100 million doses of its potential coronavirus vaccine, as it stocks up on vaccine and drugs in an attempt to tame the pandemic.

Trump says coronavirus vaccine possible before Nov. 3

U.S. President Donald Trump said on Thursday it was possible the United States would have a coronavirus vaccine before the Nov. 3 election, a more optimistic forecast on timing than anything suggested by his own White House health experts.

Trump says coronavirus vaccine possible before Nov. 3

U.S. President Donald Trump said on Thursday it was possible the United States would have a coronavirus vaccine before the Nov. 3 election, a more optimistic forecast than timing put forth by his own White House health experts.

FACTBOX-U.S., UK spend billions to take lead in securing coronavirus vaccines

The United States and United Kingdom are leading a rush to strike deals with drugmakers to reserve supplies of experimental coronavirus vaccines, as the race to develop a safe and effective vaccine reaches the final stages of testing. There are currently no approved vaccines...

Moderna prices COVID-19 vaccine at $32-$37 per dose for smaller volume deals

Moderna Inc <MRNA.O> said on Wednesday smaller volume agreements for its experimental coronavirus vaccine have been priced in the range of $32 to $37 per dose, higher than the price set by the U.S. deal for Pfizer Inc's <PFE.N> vaccine candidate.

Canada signs deals with Pfizer, Moderna for experimental COVID-19 vaccines

Canada has signed separate deals with Pfizer Inc and Moderna Inc to supply millions of doses of their experimental coronavirus vaccines, a top official said on Wednesday.

BRIEF-Canada announces deal with Moderna for supplies of its experimental coronavirus vaccine

* CANADA ANNOUNCES DEAL WITH MODERNA FOR SUPPLIES OF ITS EXPERIMENTAL MRNA-1273 CORONAVIRUS VACCINE

BioNTech, Fosun launch another COVID-19 vaccine trial

Germany's BioNTech and China's Shanghai Fosun Pharmaceutical on Wednesday announced the start of another COVID-19 vaccine trial in China with a total of 144 participants.

Large U.S. COVID-19 vaccine trials will exclude pregnant women for now

The first two COVID-19 vaccines to enter large-scale U.S. trials will not be tested in pregnant women this year, raising questions about how this vulnerable population will be protected from the coronavirus, researchers told Reuters.

FACTBOX-U.S. pours billions into securing access to coronavirus vaccine candidates

As drugmakers race to develop vaccines and therapies for the novel coronavirus, the United States is rushing to secure access to them. The U.S. government has agreed to invest more than $7 billion in vaccines and has funded more than 30 projects, including for diagnostics...

Large U.S. COVID-19 vaccine trials will exclude pregnant women for now

The first two COVID-19 vaccines to enter large-scale U.S. trials will not be tested in pregnant women this year, raising questions about how this vulnerable population will be protected from the coronavirus, researchers told Reuters.

U.S. to pay $2.1 bln to Sanofi, GSK, in COVID-19 vaccine deal

The U.S. government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drug makers' testing and manufacturing, the companies said on Friday.

Pfizer, BioNTech to supply 120 million doses of coronavirus vaccine to Japan

Pfizer Inc <PFE.N> and BioNTech SE <BNTX.O> have agreed to supply Japan with 120 million doses of their experimental coronavirus vaccine in the first half of 2021, the companies said on Friday.

Pfizer, BioNTech to supply 120 mln doses of coronavirus vaccine to Japan

Pfizer Inc and BioNTech SE have agreed to supply Japan with 120 million doses of their mRNA-based vaccine candidate against the novel coronavirus in the first half of 2021, the companies said on Friday.

'Vaccine nationalism': Is it every country for itself?

It's dog eat dog in the world of COVID-19 vaccines.

FACTBOX- The race for a coronavirus vaccine

(Adds Osaka University, Kentucky Bioprocessing, Vaxine, Medigen; Updates CureVac, J&J, GSK) July 29 (Reuters) - More than 150 vaccines are being developed and tested around the world to stop the COVID-19 pandemic, with 25 in human clinical trials, according to the World...

Moderna says COVID-19 vaccine pricing to ensure broad access

Moderna Inc plans to price its experimental coronavirus vaccine in a way that ensures broad access, it said on Wednesday, adding that it did not intend to conduct late-stage trials of the vaccine outside the United States.

Moderna says COVID-19 vaccine pricing to ensure broad access

Moderna Inc plans to price its experimental coronavirus vaccine in a way that ensures broad access, it said on Wednesday, adding that it did not intend to conduct late-stage trials of the shot outside the United States.

Germany: Coronavirus vaccine unlikely to be widely available before mid-2021

Germany awarded three biotech companies grants to help them speed up the development of coronavirus vaccine candidates, but Research Minister Anja Karliczek said any vaccine was unlikely to be widely available before the middle of next year.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up